This paper compared two human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring methods and investigated the concordance of HER2 status by fluorescent in situ hybridization (FISH) and IHC using tissue microarrays (TMAs) constructed from epithelial ovarian cancer specimens.
Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
Chao WR, Lee MY, Ruan A, Sheng HP, Hsu JD, Han CP, Koo CL
Purpose
Conclusion
IHC results were concordant between the two scoring methods for 43 of the 49 cases and the remaining six cases were classified as IHC negative under the Trastuzumab for Gastric Cancer (ToGA) resection scoring method and equivocal by the ToGA biopsy scoring method. Compared to the ToGA biopsy scoring method, use of the ToGA surgical scoring method resulted in slightly higher accuracy (97.56% vs. 97.14%) and specificity (96.97% vs. 96.30%), but did not change the sensitivity (100%, both), negative predictive value (88.9%, both), or positive predictive value (100%, both). The percentage of HER2 amplification increased with increasing HER2 staining category regardless of HER2 IHC scoring method employed. A single case was HER2 positive by both scoring methods but HER2 non-amplified by FISH.
Studies (1)
Purpose
This study compared two HER2 IHC scoring methods and investigated the concordance of HER2 status by FISH and IHC using TMAs. TMAs were constructed from 21 cases of FFPE epithelial ovarian cancer from the Chung-Shan Medical University Hospital tissue bank and 28 cores of mucinous EOC from a commercial TMA. HER2 immunostaining was performed on an autostainer. FISH staining for HER2 and CEP17 was evaluated in two separate fields containing at least 20 cells. Scoring of IHC and FISH was determined using both the ToGA surgical and ToGA biopsy scoring methods.
Summary of Findings
IHC results were concordant between the two scoring methods for 43 of 49 cases (26 HER2 negative, 8 HER2 equivocal and 9HER2 positive) and the remaining six cases were classified as IHC negative under the ToGA resection scoring method and equivocal by the ToGA biopsy scoring method. The percentage of HER2 amplification increased with increasing HER2 staining category, regardless of HER2 IHC scoring method employed (P<0.001, both). Of the eight cases classified as HER2 2+ (equivocal) by the ToGA surgical scoring method, six had no HER2 amplification and two showed HER2 amplification. Of the 14 cases classified as HER2 2+ (equivocal) by the ToGA biopsy scoring method, twelve showed no HER2 gene amplification and two showed HER2 gene amplification. A single case was HER2 positive by both scoring methods but HER2 non-amplified by FISH. Compared to the ToGA biopsy scoring method, use of the ToGA surgical scoring method resulted in slightly higher accuracy (97.56% vs. 97.14%) and specificity (96.97% vs. 96.30%), but did not change the sensitivity (100%, both), negative predictive value (88.9%, both), or positive predictive value (100%, both).
Biospecimens
TissueOvaryPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
DNAFISHProteinImmunohistochemistryPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Immunohistochemistry Specific Data handling ToGA biopsy scoring methodToGA resection scoring methodImmunohistochemistry Specific Technology platform FISH